22nd week of 2015 patent applcation highlights part 48 |
Patent application number | Title | Published |
20150148305 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. The transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels. | 2015-05-28 |
20150148306 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Type II diabetes, Type I diabetes, insulin resistance, cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, macular adema, arthritis, osteoarthritis, rheumatoid arthritis, inflammatory bowel syndrome, neudegeneration, Alzheimer's disease, Huntington's disease, Ulcerative colitis, Crohn's disease, Multiple Sclerosis, muscular dystropthy, metabolic syndrome, fatty liver, bone diseases, inflammatory diseases. | 2015-05-28 |
20150148307 | METHODS AND COMPOSITIONS FOR THE PROGNOSIS AND TREATMENT OF RELAPSED LEUKEMIA - The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject. | 2015-05-28 |
20150148308 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS - A harmful arthropod control composition comprising a compound represented by the following Formula (1) | 2015-05-28 |
20150148309 | SACCHARIDE FRACTION FROM WHEAT, ISOLATION PROCESS AND FIELD OF USE OF THE INVENTION - Fractions extracted from wheat seeds germinated and macerated in water having a molecular weight comprised between 3 and 30 K Daltons are described. | 2015-05-28 |
20150148310 | DEUTERIUM-ENRICHED HYALURONAN - The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same. | 2015-05-28 |
20150148311 | NON-SYSTEMIC TGR5 AGONISTS - Compounds having the following structure (I): | 2015-05-28 |
20150148312 | OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS - Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions. | 2015-05-28 |
20150148313 | MACROCYCLIC FACTOR VIIA INHIBITORS - The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments. | 2015-05-28 |
20150148314 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS - There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer. | 2015-05-28 |
20150148315 | Method for Improving Drug Treatments in Mammals - An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants. | 2015-05-28 |
20150148316 | LIPID MIXTURE FOR INFANT NUTRITION - The subject invention includes a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said phospholipid and uses thereof. | 2015-05-28 |
20150148317 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS - A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury. | 2015-05-28 |
20150148318 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS - A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 μM concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. | 2015-05-28 |
20150148319 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-05-28 |
20150148320 | COSMETIC USE OF SALICYLIC ACID DERIVATIVES - Cosmetic compositions comprising salicylic acid derivatives and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The salicylic acid derivatives are believed to have modulatory activity against one or more biochemical pathways implicated in the appearance of human skin. | 2015-05-28 |
20150148321 | SUBSTITUTED ANDROST-4-ENE DIONES - The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders. | 2015-05-28 |
20150148322 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, | 2015-05-28 |
20150148323 | PROGESTERONE FORMULATIONS - Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone. | 2015-05-28 |
20150148324 | FORMULATIONS FOR THE PREPARATION OF IMMEDIATE RELEASE TABLETS FOR ORAL ADMINISTRATION CONTAINING LOW-DOSE MIFEPRISTONE, TABLETS THUS OBTAINED AND THEIR PREPARATION PROCESS - Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, the tablets thus obtained and their preparation process, are described. | 2015-05-28 |
20150148325 | Depot Formulations of a Hydrophobic Active Ingredient and Methods for Preparation Thereof - The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection. | 2015-05-28 |
20150148326 | Monobactams - The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections. | 2015-05-28 |
20150148327 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS - The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R | 2015-05-28 |
20150148328 | Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof - The invention relates to the novel products of formula (I) with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH | 2015-05-28 |
20150148329 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent. | 2015-05-28 |
20150148330 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME - This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition. | 2015-05-28 |
20150148331 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT - A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease. | 2015-05-28 |
20150148332 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS - The present invention provides compounds of formula (Ia) and (Ib) | 2015-05-28 |
20150148333 | BENZO [B] ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF - The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. | 2015-05-28 |
20150148334 | HETEROARYLS AND USES THEREOF - This invention provides compounds of formula I-A or I-B: | 2015-05-28 |
20150148335 | LIQUID FORMULATION - The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension. | 2015-05-28 |
20150148336 | Methods for Selecting Medications - The invention provides methods for selecting and administering antidepressant medications to a patient based upon the patient's combination genotype and phenotype for a panel of genes. | 2015-05-28 |
20150148337 | BENZO [C] ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF - The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. | 2015-05-28 |
20150148338 | COMPOSITIONS COMPRISING SHORT-ACTING BENZODIAZEPINES - A composition is provided with a benzodiazepine and at least one hygroscopic excipient, in particular lactose and/or dextran. | 2015-05-28 |
20150148339 | GASTRIN ANTAGONISTS FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS - The provided embodiments are based in some aspects on the demonstration herein of a role for gastrin in regulating the aging gut-ovary axis and effects of targeting gastrin activity in reversing gastrin-mediated bone loss. Provided are methods, compositions and agents, including gastrin antagonists, for treatment, amelioration, and prevention of bone diseases and conditions. Methods for treating a bone disease or condition associated with hypergastrinemia in a subject in need thereof may comprise administering to the subject at least one dose of a therapeutically effective amount of a gastrin receptor-targeting agent, thereby treating the bone disease or condition associated with hypergastrinemia. | 2015-05-28 |
20150148340 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF - The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases. | 2015-05-28 |
20150148341 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 2015-05-28 |
20150148342 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2015-05-28 |
20150148343 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS - The present invention relates to novel sirtuin-modulating compounds, corresponding pharmaceutical compositions comprising a sirtuin-modulating compound, alone and/or in combination with another therapeutic agent, and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. | 2015-05-28 |
20150148344 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS - This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula I | 2015-05-28 |
20150148345 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS - Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia. | 2015-05-28 |
20150148346 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE - Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith. | 2015-05-28 |
20150148347 | INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS - A compound of formula I, | 2015-05-28 |
20150148348 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME - The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof. | 2015-05-28 |
20150148349 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF - The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 2015-05-28 |
20150148350 | DRUG FOR PREVENTING/TREATING OCULAR DISEASE - The present invention relates to a medicament for preventing or treating an ocular disease comprising cyclo-trans-4-L-hydroxyprolyl-L-serine as an active ingredient, a medicament for preventing or treating dry eye comprising the compound as an active ingredient, and, in particular, a medicament for preventing or treating dry eye having an action of enhancing mucin secretion and an action of enhancing repair of ocular tissue damage caused by dry eye. | 2015-05-28 |
20150148351 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF - The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer. | 2015-05-28 |
20150148352 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic aneurysm, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction (heart attack), peripheral vascular disease, aortic dissection, aortic stenosis, arrhythmia (irregular heartbeat), atrial fibrillation, cardiomyopathy, chest pain, claudication, congenital heart disease. | 2015-05-28 |
20150148353 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES - A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure: | 2015-05-28 |
20150148354 | CRYSTALLINE FORMS OF A PURINE DERIVATIVE - The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms. | 2015-05-28 |
20150148355 | TRANSDERMAL SILICONE GEL (SILOGEL) COMPOSITIONS AND METHODS OF PREPARATION - A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening. | 2015-05-28 |
20150148356 | COMPOUNDS FOR DRY SKIN AND ANTI-AGEING APPLICATION - The present invention relates to the cosmetic use, as agent for preventing and/or treating an aesthetic defect in the skin and/or its appendages that is associated with an imbalance in the differentiation and/or proliferation of the cells of an epidermis, of an effective amount of at least one compound represented by one of the general formulae, (Ia) or (Ib) | 2015-05-28 |
20150148357 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS - Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds. | 2015-05-28 |
20150148358 | NOVEL DGAT2 INHIBITORS - The present invention provides compounds of the Formula below: | 2015-05-28 |
20150148359 | SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS - Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells. | 2015-05-28 |
20150148360 | 3,5,N-TRIHYDROXY-ALKANAMIDE AND DERIVATIVES: METHOD FOR MAKING SAME AND USE THEREOF - The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells. | 2015-05-28 |
20150148361 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor - Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H | 2015-05-28 |
20150148362 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE - The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases. | 2015-05-28 |
20150148363 | NEW AZACYCLIC COMPOUNDS - The invention provides novel compounds having the general formula (I) | 2015-05-28 |
20150148364 | Artemisinin with Berberine Compositions and Methods of Making - An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for treatment and prevention of malaria, dengue fever, yellow fever, dysentery, Lyme disease, babesiosis, progressive multifocal leukoencephalopathy, | 2015-05-28 |
20150148365 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds - The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of alpha, beta unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. | 2015-05-28 |
20150148366 | Particulates - A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are preferably made by melt extrusion, and can have rubbery characteristics and can exhibit tamper resistance. | 2015-05-28 |
20150148367 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2015-05-28 |
20150148368 | CRYSTALLINE, ANHYDROUS FORMS OF OXYMORPHONE HYDROCHLORIDE - Crystalline, anhydrous hydrochloride salts of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and for the treatment and/or prevention of pain. | 2015-05-28 |
20150148369 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES - The current application relates to the use of a compound selected from the group consisting of camptothecin and its analog, 10-hydroxy camptothecin, topotecan, irinotecan, 18-beta-glycyrrhetinic acid and its analog, carbinoxolone, etoposide, topoisomerase inhibitors, and combinations thereof, for the treatment of a synucleinopathy disease or disorder such as Parkinson's disease. | 2015-05-28 |
20150148370 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS - The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein R | 2015-05-28 |
20150148371 | NOVEL NEUROMODULATORY COMPOUNDS - Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2015-05-28 |
20150148372 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2015-05-28 |
20150148373 | HETEROCYCLIC GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF - The invention provides heterocyclic guanidine compounds that inhibit F | 2015-05-28 |
20150148374 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF - The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 2015-05-28 |
20150148375 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2015-05-28 |
20150148376 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE - The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders. | 2015-05-28 |
20150148377 | Quinoline Derivatives - The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R | 2015-05-28 |
20150148378 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES - The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate. | 2015-05-28 |
20150148379 | Injectable Supersaturated Acetaminophen Solution for Spinal Administration - The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration. | 2015-05-28 |
20150148380 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. | 2015-05-28 |
20150148381 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES - The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing. | 2015-05-28 |
20150148382 | SEMI-SOLID TOPICAL COMPOSITION WHICH CONTAINS PIRFENIDONE AND MODIFIED DIALLYL DISULPHIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNE - The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. | 2015-05-28 |
20150148383 | Methods for Inhibiting or Reversing Epiretinal Membrane Formation - Described herein are treatment methods involving the administration of nicotinamide, which has been discovered to stabilize the normal phenotype of retinal pigment epithelial cells and to prevent retinal pigment epithelial cell proliferation. Diseases and disorders that can be treated according to the methods disclosed herein include, e.g., macular pucker, proliferative vitreoretinopathy, preretinal fibrosis, vitreomacular traction, tractional retinal detachment, and phthsis bulbi, cystoid macular edema (CME) arising from intraocular inflammation due to uveitis, vasculitis, trauma, surgery, and collagen vascular disease (e.g., Behcets disease or sarcoidosis), and age related macular degeneration. | 2015-05-28 |
20150148384 | A-RING EPOXIDIZED TRITERPENOID-BASED ANTI-INFLAMMATION MODULATORS AND METHODS OF USE THEREOF - Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided. | 2015-05-28 |
20150148385 | PHARMACEUTICAL COMPOSITION CONTAINING A COMPOUND HAVING A THROMBOPOIETIN RECEPTOR AGONISTIC ACTIVITY - The present inventor has found out that the following criteria enable to ensure an effect for increasing the platelet count while preventing an excessive increase in the platelet count; | 2015-05-28 |
20150148386 | Oxazolidinone derivatives and composition for preventing or treating Hepatitis C containing the same - The present invention relates to oxazolidinone compounds represented by Chemical Formula 1, pharmaceutically acceptable salts thereof or hydrates, a method of preparing the same, and a pharmaceutical composition for preventing or treating Hepatitis C infection: | 2015-05-28 |
20150148388 | CHEMICAL COMPOSITION - The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration, as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms. | 2015-05-28 |
20150148389 | Methods for Treating or Preventing Brain Infections - The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection. | 2015-05-28 |
20150148390 | GLIOBLASTOMA INHIBITING COMPOUNDS AND THEIR USE - The present invention relates to glioblastoma inhibiting compounds, in particular gambogic acid amid and derivatives thereof for the treatment of glioblastoma. Moreover, methods for determining whether a treatment with the compounds of the invention is suitable for a patient are disclosed. | 2015-05-28 |
20150148391 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS - The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound. | 2015-05-28 |
20150148392 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 - 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed. | 2015-05-28 |
20150148393 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN INFLAMMATION AND RELATED SYNDROMES - The invention relates to a cosmetic and/or pharmaceutical composition in combination with suitable carriers for topical use, comprising a mixture consisting of methyl sulfonyl methane and at least one compound belonging to the class of 4-alkyl cyclohexanols, which is useful in the treatment of various inflammatory conditions such as rosacea. The composition can act to simultaneously hinder both the release of chemical mediators which are up-regulated in rosacea and their action of causing the activation of TRPV receptors. The composition can reduce the effect of ultraviolet radiations on a skin already affected by an inflammatory process, and particularly, it can reduce the erythema induced by ultraviolet radiations on a skin already affected by an inflammatory process. | 2015-05-28 |
20150148394 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS - The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2015-05-28 |
20150148395 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 2015-05-28 |
20150148396 | CLONIDINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2015-05-28 |
20150148397 | CLONIDINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2015-05-28 |
20150148398 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS - The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity. | 2015-05-28 |
20150148399 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 2015-05-28 |
20150148400 | O/W-EMULSION-TYPE TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING A RETINOID - O/W-emulsion-type topical pharmaceutical compositions including a retinoid are described. Also described, is a topical pharmaceutical composition including by way of an active pharmaceutical ingredient, a retinoid in a physiologically acceptable composition. Preparation methods and the use of the same in dermatology are also described. | 2015-05-28 |
20150148401 | METHODS AND COMPOSITIONS FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS - The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells. | 2015-05-28 |
20150148402 | MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE - The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2′-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2′-Fluorine. The invention provides that the 2′-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3′ end of the molecule. | 2015-05-28 |
20150148403 | USP37 INACTIVATION AS A TREATMENT FOR PLZF/RARA-ASSOCIATED ACUTE PROMYELOCYTIC LEUKEMIA - Method of regulating the stability and/or the level of the fusion protein PLZF/RARA are disclosed. Also disclosed are methods for identifying an agent as a regulator of the stability and/or the level of the fusion protein PLZF/RARA. Methods for identifying a therapeutic agent for treating PLZF/RARA-associated acute promyelocytic leukemia (APL) is also disclosed. | 2015-05-28 |
20150148404 | RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders - The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing, delaying and/or treating a human cis-element repeat instability associated genetic neuromuscular or neurodegenerative disorder. | 2015-05-28 |
20150148405 | Expression Construct for a Lin28-Resistant Let-7 Precursor MicroRNA - Precursor microRNA molecules that have been modified to prevent a protein involved in regulating developmental timing, oncogenesis, and/or neuronal growth from blocking processing of the precursor microRNA sequence to the mature microRNA are provided. Methods and kits for using the precursor microRNA molecules also are provided. | 2015-05-28 |